Evolution and clinical impact of genetic epistasis within EGFR-mutant lung cancers
| Autor: | Victor Olivas, Petros Giannikopoulos, Thomas B.K. Watkins, Caroline E. McCoach, Kimberly C. Banks, Gareth A. Wilson, Wei Wu, Anibal Cordero, Nicholas McGranahan, Aleah F. Caulin, Hatim Husain, John St. John, Jonathan W. Riess, Julia K Rotow, Collin M. Blakely, Richard B. Lanman, Ashley Maynard, Victoria E. Wang, Nicolai Juul Birkbak, Matthew A. Gubens, David R. Gandara, Jacob J. Chabon, Beatrice Gini, Trever G. Bivona, Charles Swanton, Robert C. Doebele, Philip C. Mack, Maximilian Diehn |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0303 health sciences
Oncogene medicine.medical_treatment Wnt signaling pathway Disease Biology Bioinformatics medicine.disease medicine.disease_cause 3. Good health Targeted therapy 03 medical and health sciences 0302 clinical medicine Tumor progression 030220 oncology & carcinogenesis Cancer research medicine Lung cancer Carcinogenesis 030304 developmental biology EGFR inhibitors |
| DOI: | 10.1101/117291 |
| Popis: | The current understanding of tumorigenesis is largely centered on a monogenic driver oncogene model. This paradigm is incompatible with the prevailing clinical experience in most solid malignancies: monotherapy with a drug directed against an individual oncogenic driver typically results in incomplete clinical responses and eventual tumor progression1-7. By profiling the somatic genetic alterations present in over 2,000 cases of lung cancer, the leading cause of cancer mortality worldwide8,9, we show that combinations of functional genetic alterations, i.e. genetic collectives dominate the landscape of advanced-stage disease. We highlight this polygenic landscape and evolution of advanced-stage non-small cell lung cancer (NSCLC) through the spatial-temporal genomic profiling of 7 distinct tumor biopsy specimens and 6 plasma specimens obtained from an EGFR-mutant NSCLC patient at (1) initial diagnosis of early-stage disease, (2) metastatic progression, (3) sequential treatment and resistance to 2 EGFR inhibitors, (4) death. The comprehensive genomic analysis of this case, coupled with circulating free (cf) tumor DNA profiling of additional advanced-stage EGFR-mutant NSCLC clinical cohorts with associated treatment responses uncovered features of evolutionary selection for multiple concurrent gene alterations: including the presence of EGFR inhibitor-sensitive (EGFRL858R;EGFRexon19del) or inhibitor-resistant (EGFRT790M;EGFRC797S) forms of oncogenic EGFR along with cell cycle gene alterations (e.g. in CDK4/6, CCNE1, RB1) and activating alterations in WNT/β-catenin and PI3K pathway genes, which our data suggest can cooperatively impart non-redundant functions to limit EGFR targeted therapy response and/or promote tumor progression. Moreover, evidence of an unanticipated parallel evolution of both EGFRT790M and two distinct forms of oncogenic PIK3CA was observed. Our study provides a large-scale clinical and genetic dataset of advanced-stage EGFR-mutant NSCLC, a rationale for specific polytherapy strategies such as EGFR and CDK4/6 inhibitor co-treatment to potentially enhance clinical outcomes, and prompts a re-evaluation of the prevailing paradigm of monogenic-based molecular stratification for targeted therapy. Instead, our findings highlight an alternative model of genetic collectives that operate through epistasis to drive lung cancer progression and therapy resistance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|